Dietary and genetic interactions in the regulation of plasma lipoprotein(a)

Current Opinion in Lipidology

Volumn 10, Issue 1, 1999, Pages 35-40

  Puckey, Loretto ^a   Knight, Brian ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A; STEROID HORMONE;

DIET; FAT INTAKE; GENETIC TRANSCRIPTION; HEREDITY; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RISK FACTOR;

CORONARY DISEASE; DIETARY FATS, UNSATURATED; HUMANS; LIPOPROTEIN(A); PLASMINOGEN; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 0033005963     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199902000-00007     Document Type: Review

References (54)

1. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132-137.
2. Lawn RM, Schwartz K, Patthy L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc Natl Acad Sci U S A 1997; 94:11992-11997.
3. Djurovic S, Berg K. Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clin Genet 1997; 52:281-292. An assessment of many of the case-control and prospective studies investigating the association of Lp(a) concentration with atherosclerosis in a large variety of populations.
4. Ciccarese M, Tonolo G, Brizzi P, Secchi G, Garrucciu G, Spanedda M, et al. Serum apolipoprotein(a) concentrations and apo(a) phenotypes in patients with liver cirrhosis. Am J Gastroenterol 1998; 93:1505-1509.
5. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE, Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 1990; 85:1542-1547.
6. Knight BL, Perombelon YF, Soutar AK, Wade DP, Seed M. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis 1991; 87:227-237.
7. Reblin T, Niemeier A, Meyer N, Willnow TE, Kronenberg F, Dieplinger H, et al. Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein. J Lipid Res 1997; 38:2103-2110.
8. Knight BL. Lp(a) catabolism in hypercholesterolaemic individuals. Chem Phys Lipids 1994; 67/68:233-239.
9. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996; 98:2414-2424.
10. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, Kostner GM. Urinary excretion of apo(a) fragments: role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996; 16:905-911.
11. Kostner KM, Clodi M, Bodlaj G, Watschinger B, Horl W, Derfler K, Huber K. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest 1998; 28:447-452. A description of how patients with impaired renal function have a reduced amount of apo(a) excreted in urine.
12. Kostner KM, Oberbauer R, Hoffmann U, Stefenelli T, Maurer G, Watschinger B. Urinary excretion of apo(a) in patients after kidney transplantation. Nephrol Dial Transplant 1997; 12:2673-2678.
13. Kostner GM, Wo X, Frank S, Kostner K, Zimmermann R, Steyrer E. Metabolism of Lp(a): assembly and excretion. Clin Genet 1997; 52:347-354. A comprehensive description of the possible mechanism and site of Lp(a) catabolism.
14. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997; 100:2170-2181.
15. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996; 16:713-719. The size of the apo(a) component was a better predictor of risk in CHD patients than Lp(a) concentration.
16. Gazzaruso C, Geroldi D, Garzaniti A, Falcone C, Fratino P, Finardi G, Buscaglia P. Apolipoprotein(a) phenotypes as genetic markers of coronary atherosclerosis severity. Int J Cardiol 1998; 64:277-284.
17. Klausen IC, Sjol A, Hansen PS, Gerdes LU, Moller L, Lemming L, et al. Apolipoprotein(a) isoforms and coronary heart disease in men: A nested case-control study. Atherosclerosis 1997; 132:77-84.
18. Linden T, TaddeiPeters W, Wilhelmsen L, Herlitz J, Karlsson T, Ullstrom C, Wiklund O. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 1998; 137:175-186.
19. Thillet J, Doucet C, Chapman J, Herbeth B, Cohen D, Faure Delanef L. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: Evidence from a large population of French centenarians. Atherosclerosis 1998; 136:389-394. A study of French centenarians showing higher Lp(a) levels and smaller apo(a) isoforms than a younger population.
20. Baggio G, Donazzan S, Monti D, Mari D, Martini S, Gabelli C, et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. Faseb J 1998; 12:433-437. A study showing that centenarians do not have an excess of low-expressing apo(a) alleles.
21. Berg K, Ro OC. Lp(a) lipoprotein level and longevity. Ann Genet 1991; 34:264-269.
22. Boerwinkle E, Menzel HJ, Kraft HG, Utermann G. Genetics of the quantitative Lp(a) lipoprotein trait III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 1989; 82:73-78.
23. Kraft HG, Kochl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 1992; 90:220-230.
24. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phonotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80:458-465.
25. Lobentanz EM, Kraszai K, Gruber A, Brunner C, Muller HJ, Sattler J, et al. Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells. Biochemistry 1998; 37:5417-5425. This study indicates that the inverse relationship between Lp(a) size and concentration may be caused by the retention in the endoplasmic reticulum of a precursor form of apo(a) during maturation.
26. Perombelon YF, Soutar AK, Knight BL. Variation in lipoprotein (a) concentration associated with different apolipoprotein(a) alleles. J Clin Invest 1994; 93:1481-1492.
27. Zysow BR, GE L, Wade DP, Knight BL, Lawn RM. C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 1995; 15:58-64.
28. Kraft HG, Windegger M, Menzel HJ, Utermann G. Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. Hum Mol Genet 1998; 7:257-264. Evidence for an association between an apo(a) promoter polymorphism and plasma Lp(a) concentration in Africans.
29. Puckey LH, Lawn RM, Knight BL. Polymorphisms in the apolipoprotein(a) gene and their relationship to allele size and plasma lipoprotein(a) concentration. Hum Mol Genet 1997; 6:1099-1107. A study of several polymorphisms in the apo(a) gene promoter in both Caucasian and Indian populations. The results indicate no direct association of any particular variant with Lp(a) level. Haplotype analysis provided evidence for groups of apo(a) alleles, each with a restricted range of sizes and associated with different Lp(a) concentrations. Linkage studies give some insight into how the apo(a) protein has expanded to produce the various isoforms.
30. Mooser V, Scheer D, Marcovina SM, Wang JP, Guerra R, Cohen J, Hobbs HH. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am J Hum Genet 1997; 61:402-417. The variation in Lp(a) concentrations in African Americans, as in Caucasians, was mainly attributable to sequence changes at or near the apo(a) gene locus. There was no evidence for a single high-expressing apo(a) allele to explain the high Lp(a) concentrations in these subjects.
31. Prins J, van der Hoek YY, Biesheuvel TH, Leus FR, van Rij Kastelein J. The functional and clinical significance of the Met-> Thr substitution in Kringle IV type 10 of apolipoprotein(a). Thromb Res 1998; 90:125-130.
32. Syrris P, Schwartzman R, Kaski JC, Carter N. Polymorphism in apolipoprotein(a) kringle IV 37 (Met/Thr): Frequency in a London population and its association with coronary artery disease. Clin Cardiol 1997; 20:870-872.
33. Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM, Lawn RM. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997; 100:558-564. Transgenic mice expressing a form of apo(a) with the lysine-binding region in kringle type 10 disrupted develop far fewer lipid lesions that animals expressing the normal apo(a) gene.
34. Magnaghi P, Mihalich A, Taramelli R. Several liver specific DNase hypersensitive sites are present in the intergenic region separating human plasminogen and apoprotein(a) genes. Biochem Biophys Res Comm 1994; 205:930-935.
35. Wade DP, Puckey LH, Knight BL, Acquati F, Mihalich A, Taramelli R. Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene. J Biol Chem 1997; 272:30387-30399. A detailed investigation of two potential enhancers of apo(a) promoter activity found upstream of the apo(a) gene, and identifying one as the promoter region of an inactive LINE-1 retrotransposon. It also indicates potential sites for the action of hormones and drugs on Lp(a) levels.
36. Yang ZY, Boffelli D, Boonmark N, Schwartz K, Lawn R. Apolipoprotein(a) gene enhancer resides within a LINE element. J Biol Chem 1998; 273:891- 897.
37. Lindner T, Gragnoli C, Furuta H, Cockburn BN, Petzold C, Rietzsch H, et al. Hepatic function in a family with a nonsense mutation (R154X) in the hepatocyte nuclear factor-4 alpha 1/MODY1 gene. J Clin Invest 1997; 100:1400-1405. A description of the effect of a mutation in the hepatic transcription factor HNF-4. Subjects inheriting this mutation show a three-fold Increase in Lp(a) concentration compared to normals, though apo(a) isoforms were not determined.
38. Angelin B. Therapy for lowering lipoprotein(a) levels. Curr Opin Lipidol 1997; 8:337-341. A review discussing the efficacy of the treatment in current use for reducing Lp(a) concentrations
39. Zysow BR, Kauser K, Lawn RM, Rubanyi GM. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler Thromb Vasc Biol 1997; 17:1741-1745. An important study of the effects of steroid hormones on apo(a) gene expression, especially in the light of the discovery of potential hormone-sensitive enhancers of apo(a) promoter activity.
40. Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser MH. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): A randomised study. Br J Obstet Gynaecol 1997; 104:708-717.
41. Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998; 97:979-986.
42. Nolte W, Radisch C, Armstrong VW, Hufner M, von zur Muhlen A. The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: results of a double- blind and placebo-controlled trial. Eur J Endocrinol 1997; 137:459-466.
43. Hershkovitz E, Belotserkovsky O, Limony Y, Leiberman E, Shany S, Phillip M. Increase of serum lipoprotein (a) levels during growth hormone therapy in normal short children. Eur J Ped 1998; 157:4-7.
44. Zamboni M, Facchinetti R, Armellini F, Turcato E, Andreis I, Bosello O. Effects of visceral fat and weight loss on lipoprotein(a) concentration in subjects with obesity. Obes Res 1997; 5:332-337.
45. Tsai YH, Park S, Snook JT. Interactions among Lp(a) phenotypes, Lp(a) concentrations and lipoprotein response to fat-modified diets. J Nutr Biochem 1998; 9:106-113.
46. Lahoz C, Alonso R, Porres A, Mata P. Effect of dietary fat saturation on lipoprotein (a) plasma levels. Medicina Clinica 1998; 110:641-645.
47. Clevidence BA, Judd JT, Schaefer EJ, Jenner JL, Lichtenstein AH, Muesing RA, et al. Plasma lipoprotein (a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids. Arterioscler Thromb Vasc Biol 1997; 17:1657-1661. The most comprehensive study this year comparing the effects of various fat- based diets on Lp(a) concentration.
48. Urgert R, Weusten van der Wouw M, Hovenier R, Meyboom S, Beynen AC, Katan MB. Diterpenes from coffee beans decrease serum levels of lipoprotein(a) in humans: Results from four randomised controlled trials. Eur J Clin Nutr 1997; 51:431-436.
49. Paassilta M, Kervinen K, Rantala AO, Savolainen MJ, Lilja M, Reunanen A, Kesaniemi YA. Social alcohol consumption and low Lp(a) lipoprotein concentrations in middle aged Finnish men: population based study. BMJ 1998; 316:594-595.
50. Paassilta M, Kervinen K, Linnaluoto M, Kesaniemi YA. Alcohol withdrawal- induced change in lipoprotein(a) - Association with the growth hormone/ insulin-like growth factor-I (IGF-I)/IGF-binding protein-1 (IGFBP-1) axis. Arterioscler Thromb Vasc Biol 1998; 18:650-654.
51. Savolainen MJ, Kosaniemi YA. Effects of alcohol on lipoproteins in relation to coronary heart disease. Curr Opin Lipidol 1995; 6:243-250.
52. Berge KE, Berg K. Cardiovascular risk factors in people with different genotypes in the insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme (ACE). Clin Genet 1997; 52:422-426. A study showing that the deletion allele of the I/D polymorphism of the angiotensin- converting enzyme gene might influence the concentration of Lp(a).
53. Lingenhel A, Kraft HG, Kotze M, Peeters AV, Kronenberg F, Kruse R, Utermann G. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 1998; 6:50-60.
54. van der Hoek Y, Lingenhel A, Kraft HG, Defesche JC, Kastelein JJ, Utermann G. Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB. J Clin Invest 1997; 99:2269-2273. A sibling-pair study showing an increase in Lp(a) variability in subjects with FDB.